0001104659-22-082024.txt : 20220722
0001104659-22-082024.hdr.sgml : 20220722
20220722163348
ACCESSION NUMBER: 0001104659-22-082024
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220720
FILED AS OF DATE: 20220722
DATE AS OF CHANGE: 20220722
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Power Sean A
CENTRAL INDEX KEY: 0001538845
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32639
FILM NUMBER: 221100301
MAIL ADDRESS:
STREET 1: 787 SEVENTH AVENUE, 48TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10019
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TG THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001001316
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 363898269
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
BUSINESS PHONE: (212) 554-4484
MAIL ADDRESS:
STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
FORMER COMPANY:
FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030310
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC
DATE OF NAME CHANGE: 20000330
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19960703
4
1
tm2221660-6_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-07-20
0
0001001316
TG THERAPEUTICS, INC.
TGTX
0001538845
Power Sean A
2 GANSEVOORT STREET, 9TH FLOOR
NEW YORK
NY
10014
0
1
0
0
Chief Financial Officer
Common Stock
2022-07-20
4
A
0
75000
0
A
643483
D
Employee Stock Option (right to buy)
7.00
2022-07-20
4
A
0
200000
0
A
2027-07-20
Common Stock, par value $0.001
200000
200000
D
Reflects a grant of restricted shares, of which 1/3 will vest on 1/1/2023, 1/3 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis, and 1/3 will vest upon approval by the European Medicines Agency of ublituximab.
Includes shares of restricted Common Stock, which vest over various time periods.
Reflects a grant of options relating to 2021 service and performance, of which 1/2 will vest on 1/1/2024 and 1/2 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis.
/s/ Sean A. Power
2022-07-22